Diplomate, American Board of Neurology Clinical Neurology & Electromyography
Diplomate, American Board of Psychiatry Medical Director,
Newport Pain Treatment Center



    University College Dublin Medical School - 1968 to 1975 (combined College & Medical School)


    Internal Medicine: University Alberta Hospital, Edmonton, Canada 1975 to 1978
    Neurology: Massachusetts General Hospital, Boston, Massachusetts 1978 - 1981


    Clinical Electrophysiology, Mayo Clinic, Rochester, Minnesota


    California & Massachusetts


    American Board of Psychiatry & Neurology, 1986
    American Board of Internal Medicine, 1980
    American Board of Psychiatry & Neurology, Subspecialty in Pain Management, 2002


    1982 to Present: Private Practice in Newport Beach, California
    1988: Founded The Headache & Pain Institute specializing in the treatment of intractable headache problems. The Institute consists of neurologist, psychiatrist, behavioral psychologist, marital therapist, physical therapist and anesthesiologist. Over 9,000 patients treated.
    1990: Founded pain service at Hoag Memorial Presbyterian Hospital, Newport Beach, California.
    1990 - 1994: Co-Director, Chronic Pain Program, College Hospital, Costa Mesa, California
    1994 - Present: Director, Newport Pain Treatment Center, Newport Beach, California


    American Assoc. For the Study of Headache
    American Headache Society
    American Pain Society
    American Academy of Neurology
    National Headache Foundation
    International Assoc. For the Study of Pain
    Orange County Medical Association


    Hoag Memorial Presbyterian Hospital, Newport Beach, California


    Kohlmeir-Degos' Disease, NEJM, 1980
    Cerebral Aspergillosis, Neurology, 1981
    Mushroom Sign in Malignant Meningiomas, Journal of CT Scanning, 1981
    The Syndrome of Spontaneous Intracranial Hypotension, 1998 (In print)
    Migraine, Serotonin, and the Mind-Body Dilemma, Economics of Neuroscience, Mar 2001


    1989: GLAXO Protocol No. S2B-305: "A Multi-Center Evaluation of the Safety and Efficacy of Subcutaneous GR43175C in Patients with Acute Migraine Attacks Using a Two-Dose Regimen"

    1992: SANDOZ, Medication Study of IM DHE-45 in the treatment of migraine

    1993: SANDOZ Study No. E-301: "A Double-Blind, Controlled, Multi-Center Study to Assess the Efficacy and Safety of D.H.E. 45 (Dihydroergotamine Mesylate) Nasal Spray 2.0 mg and 3.0 mg Doses in Comparison with Placebo for the Acute Treatment of Migraine Headache"

    1993/94 GLAXO Protocol No. S2B-351: "A Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Sumatriptan Suppositories in the Acute Treatment of a Single Migraine Attack"

    1994: GLAXO Protocol S2B-342: "A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Headache Pain Relief with Sumatriptan Nasal Spray (5 mg., 10mg., and 20 mg.) Across Three Migraine Attacks"

    1995: SANDOZ Study No. DHE 454: "A Double-Blind, Randomized, Placebo-Controlled Study to Determine the Effectiveness and Safety of Dihydroergotamine Mesylate Nasal spray 2 mg for the Acute Treatment of Migraine Headache With or Without Aura in Migraineur Families"

    1993/95: GLAXO Protocol S2B-350: "Imitrex Post Marketing Surveillance Study" Sumatriptan injection

    1997: QUINTILES VML 251/96/07: "A Double-Blind, Placebo-Controlled, Parallel - Group Study to Assess the Efficacy and Safety of Up to Two Doses of VML251 in the Acute Treatment of Migraine"

    QUINTILES Protocol No. 160-103: "A Multicenter, Double-Blind, Randomized Placebo-Controlled, Parallel Group Study Of The Efficacy And Safety Of Escalating The Dose Of Oral Eletriptan In Subjects With Acute Migraine"

    QUINTILES Protocol No. 160-108: "A Multicenter, Randomized, Open Label, Comparative Study Of The Safety, Toleration And Efficacy Of Oral Eletriptan For Long Term Treatment Of Subjects With Acute Migraine".

    1999: ASTRAZENECA Protocol No. 311CUS/0003:"A Multicenter, 2 Phase Double-blind, Randomized, Placebo-Controlled, Parallel Trial to Evaluate the Efficacy of Repeated Oral Doses of Zolmitriptan as Prophylactic Treatment for Menstrual Migraine Headaches".

    GlaxoSmithKline Protocol No. S2W40012/S2W40024: "A Randomized, Double-blind, Placebo-Controlled Parallel Group Evaluation of Oral Naratriptan 1mg Twice Daily as Prophylactic Treatment for Menstrually-Associated Migraine".

    2000 POZEN Inc. Protocol No. MT100-304: "A Single Dose, Double-Blind, Safety and Efficacy Study of MT100, Metoclopramide Hydrochloride and Naproxen Sodium in Subjects with Acute Migraine Attacks".

    2000 ALLERGAN Protocol 191622-036: "A multicenter, double-blind, randomized, placebo-controlled parallel group study of the continuation of benefit of the two doses of BOTOX (botulinum Toxin, Type A) purified neurotoxin complex for the prophylactic treatment of migraine headaches."

    2000 INC Research/GLAXO Protocol S2W40027: "An open-label evaluation of the long-term safety of oral Naratriptan 1 mg twice daily as short-term prophylactic treatment for menstrually-associated migraine."

    2000-01 PAREXEL Protocol 311CUS/0003-0017: ?A multicenter, 2-pase, double-blind, randomized, placebo-controlled, parallel trial to evaluate the efficacy of repeated oral doses of Zolmitriptan (ZOMIG®) as prophylactic treatment for MENSTRUAL MIGRAINE HEDACHE.

    2001-03 ALLERGAN Protocol 191622-039: "A multi-center, double-blind, randomized, placebo-controlled parallel group study of BOTOX (Botulinum Toxin Type A) purified neurotoxin complex for the prophylactic treatment of HEADACHES in the CHRONIC HEADACHE population."

    2002 PAREXEL Trial Number: 311CUS/0003: "A Multicenter, 2-phase, Double-blind, Randomized, Placebo- controlled, Parallel Trial to Evaluate the Efficacy of a Single Dose of Solmitriptan (Zomig®) as Acute Treatment in Phase I and Repeated Doses as Preemptive Treatment in Phase II for Menstrual Migraine Headache"

    2002 - 2003 Astra- Zeneca Trial Number: 311 CUS/00022: "A Multicenter, Randomized, Placebo-controlled, Double-blind, Parallel-group Trial to Evaluate Early Efficacy and Tolerability of Zolmitriptan (ZOMIG®) Nasal Spray in the Acute Treatment of Adult Subjects with Migraine."

    Dec 2003 to Feb 2004: GlaxoSmithKline: Protocol# SUM30047: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Single Attack Study to Evaluate the Onset of Efficacy of a New Formulation of Sumitriptan Tablets 50mg and 100mg in the Acute Treatment of Migraine.

    Dec 2003 to Present: GlaxoSmithKline: Protocol# NPP30010: A Multicenter, randomized, double-blind, placebo-controlled, parallel group study to evaluate the safety and efficacy of lamotrigine in subjects with neuropathic pain and inadequate pain relief with gabapentin, tricyclic antidepressants or non-narcotic analgesics.

    Dec 2003 to Mar 2004: Merck & Co.,Inc.: Protocol# MTEP(Migraine Therapy Evaluation Protocol) : A Multicenter, Open-Label, Crossover Study Comparing MaxaltÒ (Rizatripatan Benzoate) With Usual Care Oral Migarine Medications

    Feb 2004 to June 2004: Bertek Pharmaceuticals Inc.(clinical study managed by PPD-CRO)Protocol# "IMPACT(Implications of Motor Fluctuations in Parkinson?s Patients on Chronic Therapy) Registry."

    Apr 2004 to Present: GlaxoSmithKline: Protocol#101468/228: Onset of Motor Complications

    Apr 2004 to Present: GlaxoSmithKline: Protocol#LAM40124: An Assessment of Behavioral Changes Associated with Lamotrigine and Levetiracetam in Patients with Epilepsy.

    July 2004 to Present: Ligand Pharmaceuticals: Protocol#PIND#101: AVINZA Pain Relief Study(Pain Control and Improved Functioning in Patients with Chronic Pain Treated with AVINZA).


      1990: Organized national conference on Pain at Hoag Memorial Presbyterian Hospital. Presented lecture on New Concepts in Headache Management

      1993: Organized Pain Conference at Four Seasons Hotel, Newport Beach. Presented lecture on "Enigma of Chronic Pain."

      1992 to present: Lecturing extensively for Glaxo Wellcome, Inc. on Sumatriptan to physician groups all over California.

      1997: National spokes person for Glaxo Wellcome, Inc. on Imitrex Nasal Spray. Have made numerous radio and television appearances commenting on Sumitriptan and new therapies for migraine.

      1988 to Present: Grand Rounds in all major hospitals in Orange County on headache and pain management including:
        Sept. 1990 Saddleback Memorial Hospital
        Oct. 1990 CPC Laguna Hills Hospital
        Mar. 1991, Apr. 1993 Irvine Medical Center
        Mar. 1993 St. Mary's Medical Center
        Mar. 1993 College Hospital
        June 1993 Brea Community Hospital
        Mar 1994 Garden Grove Medical Center
        Jan 1995 Hoag Memorial Presbyterian Hospital
        Jan 1995 Los Alamitos Medical Center
        June 1997 Placentia Linda Medical Center
        Feb. 1998 St. Francis Hospital, Santa Barbara
        April 1998 Western Medical Center
        May 1999 Charter Behavior Health Systems, CME Program-
        Sept. 1999 Methodist Hospital, Arcadia
        Oct. 1999 Providence Saint Joseph Medical Center, Burbank
        January 10, 2000 St Jude Medical Center Fullerton, CA
        February 15, 2000 St Mary's Regional Medical Center Grand Junction, CO
        February 25, 2000 39th Annual Convention Osteopathic Physicians & Surgeons of California -"Headache & Analgesic Withdrawal", Universal City, CA
        March 29, 200 East Los Angeles Pharmacists Association "New Treatment in Migraine & Related Disorders" Glendale, CA
        April 7, 2000 Orange County OBGYN Society, Newport Beach, CA
        May 11, 2000 Orange County Ophthalmology Society "Migraine: The Oldest Disorder, The Newest Insights"
        June 9, 2000 8th Annual Osteopathic Physicians & Surgeons, Spring Seminar "Headache & Analgesic Withdrawal", Dana Point, CA
        July 12, 2000 Regional Medical Scientist Migraine University Program "Diagnosis of Migraine" Chicago, IL
        November15, 2000 Orange County Psychiatric Society "Migraine & Depression" Santa Ana, CA

        Lectures to Associations/Societies include:

          Sept. 1990 Society of Orange County ER Physicians
          Sept. 1996 Iranian Medical Society
          Sept. 1997 American Osteopathic Family Physicians Society
          Feb. 1998 Indian Medical Society
          Feb. 1998, Obstetric & Gynecological Assembly of California
          Mar. 1998 East Los Angeles Pharmacy Association, San Gabriel Valley Pharmacy Association, Hollywood-Wilshire Pharmacy Association
          1999 Regional Migraine Consultant's Meeting, Carlsbad, CA
          1999 Migraine Regional Advisory Board Meeting, Atlanta, GA
          July 1999 Blue Cross of California Physicians, Newport Beach, CA
          Oct. 1999 Annual California Association of Physician's Assistants, Palm Springs
          1999 Regional Migraine Consultant's Meeting, Atlanta, GA - Oct. 1999
          1999 Regional Migraine Consultant's Meeting, San Diego - Oct. 1999
          1999 Regional Migraine Consultant's Meeting, Pinehurst, NC - Nov. 1999
          1999 Regional Migraine Consultant's Meeting, Phoenix, AZ - Nov 1999
          March 25, 2000 Migraine Consultant's Meeting, "Treatment of Migraine for the New Millennium" Williamsburg, VA
          April 1, 2000 Migraine Consultant's Meeting, "Treatment of Migraine for the New Millennium" Colorado Springs, CO
          April 8, 2000 Migraine & Epilepsy Summit Meeting, Anaheim, CA
          September 30, 2000 Clinical Update in Neurology: Beyond the Decade of the Brain (clinical forum) re: Neuropathic Pain Olympic Valley, CA
          October 24, 2000 Neurological Associates of West Los Angeles , Santa Monica, CA
          December 2, 2000 Southern California region Migraine Regional Advisory Board Ojai, CA
          December 6, 2000 Orange County Medical Group
          October 25-26, 2002 4th Annual Pain Management and Palliative Care Conference (in collaboration with the Southern California Cancer Pain Initiative (SCCPI)